加载中
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
前收盘价
US$2.95
−US$0.07 · -2.32%
盘前
US$2.99
+US$0.04 · +1.36%
10月8日 7:01 ET
盘中时间采用ET。市场数据可能有所延迟。
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
日内区间
当前US$2.95
52周区间
当前US$2.95
盘中时间采用ET。市场数据可能有所延迟。
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
日内区间
当前US$2.95
52周区间
当前US$2.95
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | 21万 USD | — | 51.2万 USD |
| 销货成本 | 3.6万 USD | — | 16.1万 USD | — | 38.5万 USD |
| 毛利 | −3.6万 USD | — | 4.9万 USD | — | 12.7万 USD |
| 研究与开发 | 507.1万 USD | 639.6万 USD | 476.9万 USD | 670.3万 USD | 618.97万 USD |
| 销售、一般及管理费用 | 663万 USD | 743.5万 USD | 629.1万 USD | 717.2万 USD | 707.35万 USD |
| 营业费用 | 1166.5万 USD | 1383.1万 USD | 1106万 USD | 1387.5万 USD | 1326.32万 USD |
| 利息收入 | 67.3万 USD | 113.3万 USD | 108.1万 USD | 10.4万 USD | 2322 USD |
| 利息支出 | — | — | — | 10.4万 USD | 322 USD |
| 折旧和摊销 | 3.6万 USD | 3.7万 USD | 4.6万 USD | 4.2万 USD | 5.99万 USD |
| 营业利润 | −1170.1万 USD | −1383.1万 USD | −1101.1万 USD | −1387.5万 USD | −1313.57万 USD |
| 净利润 | −1092.7万 USD | −1255.4万 USD | −981.1万 USD | −1359.5万 USD | −1294.66万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$6.00
上涨空间 103.39%报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
